Liver: diuretic agents for ascites: joining forces from the start?
Ginès
Pere
P
Liver Unit, Hospital Clinic, University of Barcelona, Institut de Investigación Biomedica August Pi I Sunyer (IDIBAPS), Centre de Investigación Biomedica en Red Enfermedades Hepáticas y Digestivas (CIBEReHD), Villarroel 17008036, Barcelona, Catalunya, Spain. pgines@clinic.ub.es
D001201:Ascites / Q000188:drug therapy* / Q000209:etiology; D002191:Canrenoic Acid / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005665:Furosemide; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage*; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000008:administration & dosage*; D013148:Spironolactone / Q000008:administration & dosage; D016896:Treatment Outcome
D000451:Mineralocorticoid Receptor Antagonists; D049994:Sodium Potassium Chloride Symporter Inhibitors; D013148:Spironolactone; D005665:Furosemide; D002191:Canrenoic Acid